FULL SITE COMING SOON
Nanocare is private biopharmaceutical company addressing the integrated roles of glycolysis and the mitochondria on cancer
Nanocare is private biopharmaceutical company addressing the integrated roles of glycolysis and the mitochondria on cancer
Nanocare ("NCT") is a development stage biopharmaceutical company focused on first-in-kind pan-cancer drugs that capitalize on the fundamental and integrated roles of glycolysis and the mitochondria on cancer survival and proliferation. NCT's patented platform offers best-in-class drugs that are broadly effective, exceptionally well tolerated, and are expected to provide a durable response, positioning the company for both monotherapy and combination therapy applications.
Nanocare's primary target is the upstream initiator of glycolysis nutrition and protector of mitochondrial cell viability specific to cancer cells. NCT's pan-cancer small molecules exhibit a unique multi-pathway mechanism to involve: (1) provoking the induction of apoptosis via influx of Ca2+ and release of Cytochrome C and Apoptosis Factor; (2) inhibiting resistance via blockage of cell signaling and macrophage transport; and (3) normalizing the tumor microenvironment and improving immune susceptibility through decreased lactate secretion and stromal cell activity.
Nanocare is following the pre-clinical success of its original formulation with more potent synthetic variants and an FDA approved carrier for greater payload, for a targeted, commercially attractive therapy.
“Mitochondrial channels have outstanding potential as targets for innovative chemotherapeutic approaches. Drugs targeting them have a selective impact on cancer cells. Focalized targeting requires modified drugs and specific nanovehicles.”
Small Molecule Modulators of Mitochondrial Channels as Chemotherapeutic Agents. Parissa S. et al, Cellular Phys and Biochem 2019; 53(S1):11-43
Copyright © 2022 Nanocare - All Rights Reserved.